Results of Phase 2 studies of zerlasiran and muvalaplin in patients with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD) have been published.1,2
Other articles available on Lp(a) Forum
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
